More than two decades ago, Professor Claude Wischik, a Professor of Psychiatric Geratology at the University of Aberdeen, and his team of bioscientists pioneered the early-stage research into tau aggregation inhibitors (TAIs) to specifically slow and halt the progression of Alzheimer’s disease. With the results of this foundational research showing promise, TauRx was founded to continue the work towards development of an effective treatment for the disease and remains closely linked to the University of Aberdeen to this day. A privately held company, TauRx’s strong research team has been established through cooperative relationships with multiple academic institutions around the world and has managed to thrive innovatively while delivering valuable results in a new era of medicine.

Having pioneered a new pathway to treating Alzheimer’s disease, TauRx presented the results of a large Phase 2 clinical trial involving 321 patients with mild and moderate Alzheimer’s in 2008. This study was conducted in the UK and Singapore and involved TauRx’s first-generation TAI, rember®. The results were reported at the Alzheimer’s Association International Conference on Alzheimer's Disease in Chicago, USA in the same year and showed that the rate of Alzheimer’s progression was reduced by 90% over a 2-year period.

These findings were tested in Phase 3 clinical trials, now completed, with the company’s second generation TAI, LMTX®. The clinical trial programme involved over 1,900 patients and comprised three separate trials: two in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia. For more information on the Phase 3 trials, please follow this link.

For further information, please visit the Science and Business Development pages of this site. 

Alzheimer’s Disease and Tau Pathology

Claude Wischik talks about how the Alzheimer’s research landscape has evolved over the past thirty years and the impact of the disease on patients and their families.